Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity. - Ozberk U; Esen SA; Sekmek S; Seven I; Bal O; Algin E; Yucel S; Uncu D (Anti-cancer drugs, 2026)